# NCT03989115 (NCT03989115)

> Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

No report yet. It can be ordered.

- Drugs tested: RMC-4630 plus cobimetinib; RMC-4630 plus osimertinib
- Indication: relapsed/refractory solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03989115
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Revolution Medicines, Inc.
- Conditions: Solid Tumor
- Interventions: RMC-4630; Cobimetinib; Drug: Osimertinib
- Enrollment: 113
- Primary outcome: Number of Participants With Adverse Events (AEs).
- Primary outcome: Number of Participants With Dose Limiting Toxicities (DLTs)

## Indexed commentary on NCT03989115 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03989115